Skip to main content

Technology@Intel

Technology@Intel

From CES Asia to Computex: Intel. Experience What’s Inside™.

Posted: 29 May 2015 01:52 PM PDT

I just came back from CES Asia in Shanghai where I got the opportunity to show how Intel is making amazing experiences possible every day. We showed off wearables, expansion in IoT, the importance of performance and graphics as well as technology like RealSense and wireless charging that would make computing smarter and more intuitive. I'm thrilled to announce that we signed an agreement with China-based Haier, one of the world's largest consumer goods manufacturers, to bring wireless charging solutions to restaurants, hotels, cafes, and even airports and planes in China later this year. These wireless charging solutions are based on the A4WP Rezence technical specifications, which allows for superior charging range and multi-device charging.

Next week, I'll be keynoting at Computex, one of the world's largest technology trade shows. Computex has been synonymous with personal computing, an area of technology that plays an integral role in our personal and work lives. But this year, we'll see innovations beyond the PC from the tech ecosystem in Taiwan and companies such as Intel, which include exciting progress in tablets, phablets, 2 in 1s, and the rise of the Internet of Things (IoT). At Computex, the fruits of this ingenuity, creativity and competition will be on full display.

Innovation in Taiwan, which has global impact, traditionally starts in PCs but is now often applied quickly to such areas as data centers and IoT. At the same time, new ecosystems and solutions are emerging to expressly support IoT and other areas.

The innovation around IoT are indeed one of the key areas to watch at the show. Intel has been a major player and you'll hear more from us on that front, as well as how the company works with the Taiwan ecosystem to bring progress to the IoT space. Intel and our customers at the show will showcase some of these deployments to demonstrate how IoT delivers in concrete ways.

Want to see how Intel RealSense technology is reinventing how people interact with devices? Want a fully wireless PC? Want to get a glimpse of Intel-powered devices expected to launch in the very near future? Do you like thinner, lighter and sleeker devices? Expect announcements and demos on these and other topics from Intel and our partners as well. I invite you to watch my keynote (2 pm on June 2, local time; also available via webcast) to find out more about how the Taiwan ecosystem and Intel are enabling smarter living by driving innovation in devices, IoT, data centers and beyond. Intel's Computex Showcase and IOT Media Event ( June 3rd) will provide further visibility into collaborations with our partners and customers in driving solutions based on Intel technology. More details on Intel at Computex 2015 can be found in this Intel media advisory.

The technology landscape is shifting and creating a wealth of opportunity and those who are innovative and nimble will benefit. It's an exciting time and, in the end, consumers are the big winners.

The post From CES Asia to Computex: Intel. Experience What's Inside™. appeared first on Technology@Intel.

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More